Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors.
Existing strategies for gene therapy in the treatment of Parkinson's disease include the delivery of genes encoding dopamine (DA)-synthesising enzymes, leading to localised production of DA in the striatum; genes encoding factors that protect nigral neurons against ongoing degeneration, such as glial cell line-derived neurotrophic factor; and genes encoding proteins that produce the inhibitory transmitter gamma-aminobutylic acid (GABA) in the subthalamic nucleus (STN), thus suppressing the hyperactive STN. Recombinant adeno-associated viral (rAAV) vectors, which are derived from non-pathogenic viruses, have been shown to be suitable for clinical trials. These rAAVs have been found to transduce substantial numbers of neurons efficiently and to express transgenes in mammalian brains for long periods of time, with minimum inflammatory and immunological responses. In vivo imaging using positron emission tomography is useful for monitoring transgene expression and for assessing the functional effects of gene delivery. Vector systems that regulate transgene expression are necessary to increase safety in clinical applications, and the development of such systems is in progress.
Muramatsu
Shin-ichi
S
Division of Neurology, Department of Medicine, Jichi Medical School, 3311-1 Yakushiji, Minami-kawachi, Tochigi, 3290498, Japan. muramats@jichi.ac.jp
Tsukada
Hideo
H
Nakano
Imaharu
I
Ozawa
Keiya
K
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics* / Q000627:therapeutic use; D006801:Humans; D010300:Parkinson Disease / Q000235:genetics* / Q000628:therapy; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use
D011994:Recombinant Proteins